



CryoLife, Inc. Appoints Gerald B. Seery President, CryoLife Europa, Ltd.

March 11, 2002

ATLANTA, Mar 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced that it has appointed Gerald B. Seery as President and CEO of its European subsidiary, CryoLife Europa, Ltd.

Mr. Seery, a native of Long Island, New York, joined CryoLife as Director of Vascular Marketing in 1993. In August 1995, he was appointed Vice President of Marketing, a position he held until March of 2001 when he was appointed President of AuraZyme Pharmaceuticals(R), Inc., a subsidiary of CryoLife, Inc., which position he held for one year. He earned his undergraduate degree in Economics from The Catholic University of America in Washington, DC, and holds an MBA in Marketing from Columbia University of New York City.

In making the appointment, Steven G. Anderson, CryoLife's founder and CEO, commented, "Gerry Seery has made significant contributions to the success of CryoLife during his tenure with the Company. I feel that he will be a dynamic leader of our European subsidiary, which is responsible for the market introduction of all of our new tissue engineering implantable devices and our family of surgical adhesive products." Mr. Seery and his family will be relocating to England where the Company maintains a distribution and physician training facility at Fareham, England.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve and the SynerGraft vascular graft, the world's first tissue-engineered heart valve and vascular replacements, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: <http://www.cryolife.com>

Contact: D. Ashley Lee
Vice President, Chief Financial Officer
(800) 438-8285

MAKE YOUR OPINION COUNT - [Click Here](#)
<http://tbutton.prnewswire.com/prn/11690X15347711>

SOURCE CryoLife, Inc.

CONTACT: D. Ashley Lee, Vice President, Chief Financial Officer of
CryoLife, Inc., + 800-438-8285

URL: <http://www.cryolife.com>
<http://www.prnewswire.com>

Copyright (C) 2002 PR Newswire. All rights reserved.